

# EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma\*

Werner Kempf,<sup>1,2</sup> †Katrin Pfaltz,<sup>2</sup> †Maarten H. Vermeer,<sup>3</sup> Antonio Cozzio,<sup>1</sup> Pablo L. Ortiz-Romero,<sup>4</sup> Martine Bagot,<sup>5</sup> Elise Olsen,<sup>6</sup> Youn H. Kim,<sup>7</sup> Reinhard Dummer,<sup>1</sup> Nicola Pimpinelli,<sup>8</sup> Sean Whittaker,<sup>9</sup> Emilia Hodak,<sup>10</sup> Lorenzo Cerroni,<sup>11</sup> Emilio Berti,<sup>12</sup> Steve Horwitz,<sup>13</sup> H. Miles Prince,<sup>14</sup> Joan Guitart,<sup>15</sup> Teresa Estrach,<sup>16</sup> José A. Sanches,<sup>17</sup> Madeleine Duvic,<sup>18</sup> Annamari Ranki,<sup>19</sup> Brigitte Dreno,<sup>20</sup> Sonja Ostheeren-Michaelis,<sup>2</sup> Robert Knobler,<sup>21</sup> Gary Wood,<sup>22</sup> and Rein Willemze<sup>3</sup>

<sup>1</sup>Department of Dermatology, University Hospital Zürich, Zürich, Switzerland; <sup>2</sup>Kempf and Pfaltz, Histological Diagnostics, Research Unit, Zürich, Switzerland; <sup>3</sup>Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands; <sup>4</sup>Department of Dermatology, Hospital 12 de Octubre, Madrid, Spain; <sup>5</sup>Department of Dermatology, Hôpital Saint Louis, Paris, France; <sup>6</sup>Department of Medicine, Divisions of Dermatology and Oncology, Duke University Medical Center, Durham, NC; <sup>7</sup>Department of Dermatology, Stanford Comprehensive Cancer Center, Stanford, CA; <sup>8</sup>Department of Dermatological Sciences, University of Florence, Florence, Italy; <sup>9</sup>Skin Tumour Unit, St Thomas' Hospital, London, United Kingdom; <sup>10</sup>Department of Dermatology, Tel Aviv University, Tel Aviv, Israel; <sup>11</sup>Department of Dermatology, Medical University, Graz, Austria; <sup>12</sup>Department of Dermatology, University of Milano-Bicocca, Istituti di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore di Milano, Milano, Italy; <sup>13</sup>Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY; <sup>14</sup>Peter MacCallum Cancer Centre, East Melbourne, Australia; <sup>15</sup>Department of Dermatology, Northwestern University, Chicago, IL; <sup>16</sup>Department of Dermatology, Hospital Clínico, University of Barcelona, Barcelona, Spain; <sup>17</sup>Department of Dermatology, University of São Paulo, São Paulo, Brazil; <sup>18</sup>Department of Dermatology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; <sup>19</sup>Department of Dermatology and Venereal Diseases, Helsinki University Hospital, Helsinki, Finland; <sup>20</sup>Department of Dermatology, University Hospital Nantes, Nantes, France; <sup>21</sup>Department of Dermatology, University of Vienna Medical School, University of Vienna, Vienna, Austria; and <sup>22</sup>Department of Dermatology, University of Wisconsin, Madison, WI

**Primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders (CD30<sup>+</sup> LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30<sup>+</sup> LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or**

**case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30<sup>+</sup> LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous**

**Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30<sup>+</sup> LPDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30<sup>+</sup> LPDs. (*Blood*. 2011;118(15):4024-4035)**

## Introduction

Primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders (CD30<sup>+</sup> LPDs) are the second most common form of cutaneous T-cell lymphomas (CTCLs) and represent a spectrum of diseases, including lymphomatoid papulosis (LYP) and primary cutaneous anaplastic large-cell lymphoma (PCALCL).<sup>1-3</sup> LYP and PCALCL share the expression of CD30 antigen as a common immunophenotypic hallmark and exhibit an excellent prognosis but differ in regard to their clinical presentation. LYP is characterized by a chronic course of years to decades of recurrent papulonodular lesions (Figure 1), each of which undergoes spontaneous regression after weeks or months. Survival is unaffected, but patients with LYP are at risk for second cutaneous or nodal lymphoid malignancies, including mycosis fungoides (MF), cutaneous or nodal anaplastic large-cell

lymphoma (ALCL), and Hodgkin lymphoma. These LYP-associated lymphomas, which are clonally related in some cases, develop in 4%-25% of affected patients and may occur before, concurrent with, or after the onset of LYP.<sup>4,5</sup>

PCALCL manifests in most patients with a solitary or grouped, rapidly growing and ulcerating large tumors or thick plaques (Figure 2). Rarely, the disease manifests with multifocal lesions. Spontaneous complete or partial regression of the tumor(s) is reported in up to 44% of the patients.<sup>4,6</sup> In contrast to its nodal counterpart, PCALCL has a favorable prognosis with 5-year survival rates between 76% and 96%.<sup>7</sup> Based on the data of one study on a limited number of patients, involvement of locoregional lymph nodes is not associated with a worse prognosis than

Submitted May 22, 2011; accepted July 26, 2011. Prepublished online as *Blood* First Edition paper, August 12, 2011; DOI 10.1182/blood-2011-05-351346.

\*The groups involved in the consensus recommendations are as follows: European Organization for Research and Treatment of Cancer (EORTC), International Society of Cutaneous Lymphoma (ISCL), and United States Cutaneous Lymphoma Consortium (USCLC).

†K.P. and M.H.V. contributed equally to this study.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2011 by The American Society of Hematology



**Figure 1. LYP: Grouped papules in the knee region.** Note scars and hyperpigmentation as residual changes after spontaneous regression of the lesions. Clinical image was captured using a digital camera (Nikon Coolpix 995; Nikon).

cutaneous involvement alone.<sup>4</sup> Skin-limited relapses are found in 39% of patients and extracutaneous spread in 13% of the patients.<sup>8</sup>

A broad variety of therapeutic approaches have been reported for CD30<sup>+</sup> LPDs. UV light phototherapy and low-dose methotrexate (MTX) are commonly used therapies for LYP, but relapses are common and sustained CRs are rarely achieved.<sup>9</sup> In PCALCL, surgical excision and radiotherapy are most commonly used for solitary tumors, whereas chemotherapy is given for multifocal disease. The histologic findings of both LYP and PCALCL with large pleomorphic and anaplastic lymphoid tumor cells and the clinical appearance with rapidly growing or multiple lesions may result in misinterpretation as a highly malignant cutaneous or even systemic T-cell non-Hodgkin lymphoma, leading to recommendations for multiagent chemotherapy or even bone marrow transplantation.<sup>10,11</sup> In addition, the increased incidence of second lymphoid neoplasms in LYP patients has been used as support for early and more intense treatment of LYP.<sup>12,13</sup>

Although a broad spectrum of therapy regimens has been reported, these have been limited to small cohort series or case reports. Indeed, there are little data from prospective controlled or



**Figure 2. PCALCL: Solitary ulcerated nodule on the leg.** Clinical image was captured using a digital camera (Nikon Coolpix 995; Nikon).

multicenter studies in CD30<sup>+</sup> LPDs. Furthermore, the response rate to treatment, recurrence rate, and outcome have not been analyzed in a systematic review. Recommendations for the treatment of CD30<sup>+</sup> LPDs previously have been published,<sup>4,5,14</sup> but international guidelines for the treatment of CD30<sup>+</sup> LPDs have not yet been established. This article reviews the therapeutic regimens reported in the literature by focusing on response rates to initial treatment, recurrence rates, and follow-up. Recommendations for the management of CD30<sup>+</sup> LPDs are presented based on these data and the expertise of the members of the European Organization for Research and Treatment of Cancer (EORTC), the International Society for Cutaneous Lymphomas (ISCL), and the United States Cutaneous Lymphoma Consortium (USCLC).

## Development process of recommendations

To identify relevant reports on the treatment of CD30<sup>+</sup> LPDs, a search in Pub Med was performed using the following terms: lymphomatoid papulosis, cutaneous lymphoma, large-cell, anaplastic, CD30, treatment, and therapy. References were selected that reported detailed data on the initial treatment, response to treatment, relapse rates, and outcome. Case reports and retrospective case series describing treatment results with follow-up and response, and results from uncontrolled and controlled interventional studies published until April 2011 were included because the number of prospective studies in CD30<sup>+</sup> LPDs is very small. Articles with only general statements, which did not allow extraction of detailed data, review articles merely reporting previous literature, and meeting abstracts were excluded. Because the data of some patients have been included in multiple reports (R.W., personal oral communication), the exact number of patients could not be determined with certainty. Documentation of response to treatment was often not reported according to current oncology standards. Instead of defined endpoints, several studies described the responses in general terms, such as “good clinical effect,” “improvement of skin lesions,” or “alive and well.”

The included articles were stratified for the level of evidence according to the Oxford Center for Evidence-based Medicine ([www.cebm.net](http://www.cebm.net)). Only cases with unequivocal diagnosis of LYP or PCALCL according to the defining criteria (Table 1) were included in further analysis. Patients presenting with nodal or other extracutaneous involvement at diagnosis or staging, secondary cutaneous ALCL, and immunosuppression-associated forms of CD30<sup>+</sup> LPDs were excluded.

Based on these data and the previously published recommendations by national expert groups,<sup>4</sup> a proposal for the recommendations was presented to the EORTC Cutaneous Lymphoma Task Force, the Board of Directors of the ISCL, and the USCLC and modified based on modifications by these members of the societies.

## Diagnosis and staging of CD30<sup>+</sup> LPDs

### Diagnostic procedure

The diagnostic criteria for CD30<sup>+</sup> LPDs are outlined in Table 1. Histologic examination is the first diagnostic step in the diagnostic workup of clinically suspected CD30<sup>+</sup> LPDs. As for other forms of cutaneous lymphomas, either complete excision (eg, a papule or small nodule in LYP) or an incisional biopsy (spindle-shaped biopsy of adequate length and depth or a punch biopsy of at least 4 mm) is recommended to allow appropriate histologic workup.

**Table 1. Diagnostic criteria for CD30<sup>+</sup> LPD**

<b>LYP</b>	
Clinical criteria	
Recurrent self-healing grouped or disseminated papulonodular skin lesions	
Note: Self-healing is defined as spontaneous regression of each individual tumor lesion within weeks or months, whether or not new lesions occur.	
LYP may manifest concurrently with MF, which is typically characterized by patches and eventually plaques or tumors.	
Histologic criteria	
LYP type A: Wedge-shaped infiltrate with scattered or clustered CD30 <sup>+</sup> tumor cells, intermingled with numerous inflammatory cells, such as small lymphocytes, neutrophils, eosinophils, and histiocytes (Figures 3 and 4). Type A is the most common histologic presentation.	
LYP type B: Epidermotropic infiltrate of small atypical CD30 <sup>+</sup> or CD30 <sup>-</sup> lymphoid cells with cerebriform nuclei that histologically resembles MF.	
LYP type C: Cohesive sheets of CD30 <sup>+</sup> large atypical lymphoid cells with only a few admixed reactive inflammatory cells.	
LYP type D: Epidermotropic infiltrate of small- to medium-sized atypical CD8 <sup>+</sup> and CD30 <sup>+</sup> lymphoid cells that histologically resembles primary cutaneous aggressive epidermotropic CD8 <sup>+</sup> cytotoxic T-cell lymphoma.	
Immunophenotypically, CD30 <sup>+</sup> tumor cells express CD4 in most cases, but CD8 <sup>+</sup> or CD56 <sup>+</sup> phenotypes have been reported. <sup>69</sup> T-cell-associated antigens, such as CD45RO, are expressed with variable loss of pan-T-cell antigens (CD2, CD3, CD5) in LYP.	
Note: There is a broad differential diagnosis because the presence of large atypically appearing CD30 <sup>+</sup> lymphoid cells is not restricted to CD30 <sup>+</sup> LPD but is seen in various inflammatory and infectious disorders. <sup>17</sup>	
<b>PCALCL</b>	
Clinical criteria	
Solitary, grouped, or multifocal nodular lesions	
No clinical evidence of LYP, MF, or other types of CTCL	
Absence of extracutaneous involvement assessed by staging procedures	
Histologic criteria	
Dense nodular dermal infiltrate composed of large pleomorphic, anaplastic, or immunoblastic cells with large, irregularly shaped nuclei and abundant pale or eosinophilic cytoplasm (Figure 5). Clusters of small reactive lymphocytes and eosinophils may be found within and surrounding the tumor cells.	
Immunophenotypically, CD30 <sup>+</sup> is expressed by at least 75% of tumor cells. In addition, CD4 or CD8 is expressed in most cases with variable loss of pan-T-cell antigens (CD2, CD3, CD5).	
Note: In contrast to nodal ALCL, primary cutaneous forms of ALCL lack epithelial membrane antigen and express the cutaneous lymphocyte antigen (HECA-452). Anaplastic lymphoma kinase [ALK-1 (p80)] and t(2;5) translocation are usually absent in PCALCL. If these are present, one needs to be highly suspicious of the lesions being a cutaneous manifestation of underlying systemic ALCL.	
Borderline cases	
Cases in which, despite careful clinicopathologic correlation, a definite distinction cannot be made at the time of diagnosis. In most cases, the final diagnosis can be achieved during follow-up based on clinical behavior.	
Note: It can be challenging and, in individual cases, even impossible to differentiate between LYP and PCALCL in patients presenting with a short history of multifocal papulonodular lesions because, although spontaneous regression of tumors is a hallmark of LYP, this has also been observed in patients with multifocal PCALCL.	


The final diagnosis should always be based on a careful clinicopathologic correlation.

The histologic features of LYP are variable and depend on the evolution of the lesions. Four histologic subtypes (A-D) have been delineated, which represent a spectrum with overlapping features and may be present in individual patients at the same time<sup>15,16</sup> (Table 1). Immunohistochemistry plays a pivotal role by revealing the presence of CD30<sup>+</sup> large pleomorphic or anaplastic T cells. By definition, CD30 is expressed by at least 75% of the tumor cells in PCALCL.<sup>1-3</sup> Differentiation of LYP and PCALCL from other forms


of CTCL and secondary cutaneous involvement by nodal Hodgkin lymphoma or systemic ALCL requires careful clinicopathologic correlation.<sup>17,18</sup>

### Staging

Staging should begin with a complete history, including previous lymphoid neoplasms (in particular Hodgkin lymphoma and MF), B-symptoms, and a careful physical examination (Table 2). Patients



**Figure 3. LYP: Large pleomorphic and anaplastic tumor cells intermingled with small lymphocytes, eosinophils, and histiocytes (hematoxylin and eosin, original magnification ×200).** Histologic photomicrograph was captured using a digital camera (AxioCam MRc5; Zeiss) mounted on an Olympus microscope (BX45; Olympus). Objective lens: 400×/0.75 NA. Imaging software: Axio Vision Release 4.8.2 (Zeiss) and Adobe Photoshop Version 8.0 (Adobe Systems).




**Figure 4. LYP: Expression of CD30 by scattered and clustered pleomorphic tumor cells.** Histologic photomicrograph was captured using a digital camera (AxioCam MRc5; Zeiss) mounted on an Olympus microscope (BX45; Olympus). Objective lens: 400×/0.75 NA. Imaging software: Axio Vision Release 4.8.2 (Zeiss) and Adobe Photoshop Version 8.0 (Adobe Systems).

**Table 2. Diagnostic workup of CD30<sup>+</sup> LPD**

Histologic features compatible with LYP or PCALCL	
History	
Wax and waning of lesions (ie, spontaneous regression of each lesion within weeks to months) with new ones developing	
Previous lymphoid neoplasms, particularly Hodgkin lymphoma, nodal anaplastic large cell lymphoma, and MF	
Immunosuppression (HIV, organ transplantation, or other conditions associated with immunosuppressive therapy, immunosuppression-related CD30 <sup>+</sup> LPDs)	
B symptoms (fever, night sweats, weight loss)	
Physical examination	
Size and number of lesions	
Presence of patches and/or plaques indicates possibility of associated MF.	
It is necessary to differentiate MF with transformation (CD30 may be expressed by large tumor cells in transformed MF) from CD30 <sup>+</sup> LPD.	
Enlarged lymph nodes (see point F)	
Hepatic or splenic enlargement	
Laboratory investigations	
Complete blood cell count and differential	
Blood chemistries, including LDH	
Serology for HTLV-1/2 (only in areas with endemic HTLV infection) to identify adult T-cell lymphoma/leukemia, in which expression of CD30 by tumor cells can occur	
Radiologic examinations	
LYP: Radiologic examinations (chest x-ray, ultrasound abdomen and pelvis, or CT scan) are considered as optional examinations in patients with typical LYP and absence of palpable enlarged lymph nodes, absence of hepatosplenomegaly, normal laboratory tests, and absence of B symptoms.	
PCALCL: Contrast-enhanced CT scan with or without positron emission tomography (chest, abdomen, pelvis) or whole-body integrated positron emission tomography/CT.	
Bone marrow aspirate or biopsy	
LYP: Not performed in patients with typical LYP	
PCALCL: Optional in patients with solitary PCALCL or patients with PCALCL without extracutaneous involvement in radiologic examinations (D) <sup>19</sup>	
Lymph node biopsy: If enlarged lymph nodes (defined as > 1.5 cm in greatest transverse [long axis] diameter) are palpable or enlarged lymph nodes are detected on radiologic examination.	

Adapted from Bekkenk et al.<sup>4</sup>

with suspected LYP should be asked for waxing and waning of recurrent papulonodular lesions within weeks. Recommended laboratory studies include a complete blood cell count with differential, blood chemistry, and lactate dehydrogenase. In LYP patients with the typical manifestation of papulonodular skin lesions and spontaneous regression of individual lesions after a few weeks and nothing on physical examination or blood tests to suggest extracutaneous disease, there is no need for the radiologic staging examination or bone marrow biopsy. However, where physical examination or laboratory tests are suggestive of extracutaneous disease in LYP, lymph node sonography, chest x-ray, CT, or positron emission tomography/CT scan should be performed. In patients with PCALCL, adequate imaging studies (contrast-enhanced CT scan with or without positron emission tomography, or whole body integrated positron emission tomography) should be



**Figure 5. PCALCL: Cohesive sheets of anaplastic lymphoid cells H&E, original magnification ×200.** The histologic photomicrograph was captured using a digital camera (AxioCam MRc5; Zeiss) mounted on an Olympus microscope (BX45; Olympus). Objective lens: 400×/0.75 NA. Imaging software: Axio Vision Release 4.8.2 (Zeiss) and Adobe Photoshop Version 8.0 (Adobe Systems Inc).

performed. In both LYP and ALCL, a lymph node biopsy should be performed if a suggestion of nodal lymphoma exists. Recent data indicate that bone marrow examination has limited value in the staging of patients with an ALCL first presenting in the skin and may therefore be reserved for selected cases with multifocal tumors, unexplained abnormal hematologic results, and those in whom extracutaneous disease is documented.<sup>19</sup>

Staging according to the Ann Arbor staging system or TNM staging system categorizes patients with nonregional LYP and patients with multifocal PCALCL as stage IV, which would imply advanced disease and unfavorable prognosis. The prognosis of both LYP and PCALCL, including its multifocal forms, is excellent so that these staging systems do not reflect the biology of the diseases. We therefore recommend documentation of CD30<sup>+</sup> LPDs according to the recently published ISCL/EORTC recommendations for staging of cutaneous lymphomas other than MF/Sézary syndrome.<sup>20</sup>

## Therapy results

For PCALCL, 52 of 161 references were selected for further analysis. These references included 23 case reports (44%), 23 (retrospective) cohort series (44%), and 6 prospective therapeutic trials (12%), including a total of 368 patients. For LYP, 207 references matching the search terms were retrieved. Sixty-two reports were selected for further analysis. These included 27 case reports (44%), 30 (retrospective) cohort series (48%), and 5 prospective therapeutic trials (8%). Because the majority of reported data are from case reports and retrospective cohort series, evidence was scored as level 4 or 5 for the majority of the reports and grades of recommendation were primarily of the C or D category.

**Table 3. PCALCL: therapies and results**

Therapy	References	No. of patients	CR, no. (%)	Relapse rate, no. (%)
SE	8,21-25,27-29,36	53	27/27 (100)	19/44 (43)
RT	8,21-23,25,30-35	32	19/20 (95)	9/22 (41)
Multiagent chemotherapy	21,24,25,27,28,37,39-43,45,57,102,103	53	35/39 (90)	16/26 (62)

The data of larger cohort studies, which each included > 30 patients, did not allow conclusions to be drawn on the effect of the chosen therapies because response and relapse rates as well as follow-up data were not separated with regard to the therapeutic modalities. Patients with LYP and patients with relapsing PCALCL often have been treated with various therapies subsequently or concurrently, making it impossible to determine which of the therapeutic interventions was the most effective in inducing partial or CR.

## Therapy of PCALCL results

Surgical excision (SE) and radiotherapy (RT) are the most common and best documented therapies for solitary or localized PCALCL. Chemotherapeutic approaches have been used mainly in patients with multifocal or relapsing disease. The number of patients per therapeutic modality and the response and relapse rates for the best documented and most widely used therapies are given in Table 3. Anecdotal reports with only 1 or 2 patients and reports on other therapies, for which mostly < 10 patients were reported, are listed in Table 4. Because of the small number of patients, these data did not allow conclusions to be drawn on the efficacy of treatment.

### Surgical excision

SE alone as initial therapy was the most common approach and was used in 19%-57% of the patients.<sup>4,8,21-28</sup> Fifty-three patients treated with SE alone could be further analyzed. Because SE was performed with the intention to remove the entire tumor, no response rates were provided, except for 2 studies reporting complete remission (CR) as initial response to SE in all of 27 patients.<sup>8,23</sup> No information was given regarding the margins of excision. Relapses occurred in 19 of 44 patients (43%).<sup>8,21-23,25,27,28</sup> Most reports do not state whether the relapses occurred at the treated site or at other sites. Two or more relapses limited to the skin were found in 7 of 11 patients.<sup>23</sup> Delay to first relapse ranged from 2-76 months.<sup>23,27,28</sup> Seventy-eight percent (32 of 41) of the patients were alive without disease after a median follow-up of 39 months (range, 4-109 months).<sup>22-25,27,29</sup>

**Table 4. PCALCL: other treatments**

Therapy	References
Isotretinoin (synonym: 13-cis-retinoic acid)	31,55
Bexarotene, alone or in combination with IFN- $\alpha$	39,50,52
IFN- $\alpha$ , IFN- $\gamma$	39,50,51,93
Topical imiquimod 5%	53,54
Thalidomide	55
Single-agent chemotherapy: gemcitabine, etoposide, intralesional and systemic MTX	38,40,44,46,104,105
Bone marrow or stem cell transplantation	4,6,8,40,41
Anti-CD30 antibody (SGN30)	40,47,48
Oral steroids	52
Excimer laser (308 nm)	106
Local thermotherapy	107

### RT

RT was applied as first-line monotherapy for PCALCL in up to 48% of the patients.<sup>4,22,23,25,26</sup> The radiation dose ranged from 30-46 Gy with a median diameter of the lesional region of 3 cm and a 2- to 3-cm margin of uninvolved perilesional skin.<sup>30</sup> RT with a dose of 40 Gy in 2-Gy fractions was reported to be well tolerated with only mild and transient side effects.<sup>30</sup> The only recorded toxicity was radiation dermatitis grade 1 to 2 seen in all patients.<sup>30</sup> CR occurred in 19 of 20 patients (95%) for whom detailed data on response were reported.<sup>8,22,30-35</sup> Recurrences were observed in 9 of 22 patients (41%) after a median follow-up period of 22 months (range, 5-95 months).<sup>8,22,23,25,32,34,35</sup> One study reported a disease-free duration to first relapse of 14 months (range, 2-59 months) in 4 patients with skin-limited relapses.<sup>23</sup> Data of 11 patients with PCALCL treated with SE followed by RT could be analyzed<sup>21,23,25,36</sup> with a sustained CR in 4 of 6 patients (67%), for whom response rates were available. The recurrence rate after treatment with SE and RT was 64% (7 of 11 patients) with a disease-free period to first relapse of 34 months (range, 8-54 months).<sup>21,23,25,36</sup>

### Chemotherapy

Fifty-three patients, for whom detailed data had been documented, were treated with multiagent chemotherapy. CR rate to multiagent chemotherapy was 92% (36 of 39 patients). Relapses were reported in 16 of 26 patients (62%). Disease-free time to relapse, which was only reported for 4 patients, was 4 months (median; range, 1-12 months).<sup>27,37-39</sup> Doxorubicin-based multiagent chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) was applied as initial therapy was separately analyzed. CHOP resulted in CR in 11 of 13 patients (85%) and relapses in 5 of 7 patients (71%).<sup>8,28,37,39-43</sup> The median duration of remission was only 6 weeks (range, 4-8 weeks; 3 patients).

Multiagent chemotherapy has been considered as first-line therapy for multifocal PCALCL. Eight of 10 patients (80%) with multifocal PCALCL treated with multiagent chemotherapy (various regimens) had relapses in the skin and/or involvement of lymph nodes.<sup>22,24-26,40,44,45</sup> There are only limited data on treatment of extracutaneous spread in PCALCL. Chou et al reported 2 patients with PCALCL and subsequent involvement of lymph nodes who were in CR after CHOP and radiation therapy, but relapses occurred in both patients after a few months.<sup>31</sup>

Single-agent chemotherapy reported in PCALCL includes MTX, etoposide and gemcitabine (Table 4). Low-dose MTX is widely used for LYP, but there are only anecdotal reports on its use in PCALCL.<sup>38,46</sup>

### Monoclonal antibodies

SGN-30, a chimeric monoclonal antibody to CD30, has been used in 13 patients with PCALCL.<sup>40,47,48</sup> In an open-label multicenter phase 2 study, 6 of 11 (55%) patients achieved CR and 3 of 11 (27%) patients showed partial remission (PR).<sup>48</sup> No disease progression was observed. The treatment was well tolerated.

**Table 5. Recommendations for the treatment (standard therapies) of CD30+ LPD**

PCALCL			LYP	
Solitary or grouped lesion(s)	Multifocal lesions	Extracutaneous spread	Localized/regional or few lesions*	Numerous and/or generalized lesions
SE	Methotrexate	Single or multiagent chemotherapy‡	Observation	Observation
RT	Alternatives: retinoids, interferon†		Phototherapy§ Topical steroids	Phototherapy§ Methotrexate Topical steroids Alternatives†: retinoids, interferon

\*For larger (defined as > 2 cm in diameter) and persistent (defined as duration of lesion > 12 weeks) lesions, SE or RT may represent alternatives.

†These therapies are of low-level evidence other than expert opinion.

‡In cases of skin and only local node involvement in PCALCL, one could consider addition of local nodal radiation <sup>4</sup>

§PUVA is best documented. Alternatively, treatment with other types of phototherapy (eg, UVB-narrow band) can be tried (evidence level 5).

Brentuximab vedotin (SGN-35) is the same monoclonal antibody linked to the antitubulin agent monomethyl auristatin E, which enhances the antitumoral activity of CD30-directed therapy. In a phase 1 study, brentuximab vedotin induced durable responses and resulted in tumor regression in most patients with relapsed or refractory CD30-positive lymphomas.<sup>49</sup>

**Other treatments**

Data on other therapeutic strategies (Table 4), such as interferons, imiquimod, retinoids, bexarotene, thalidomide, and bone marrow transplantation, are very limited and do not allow conclusions to be drawn on their effectiveness.<sup>4,6,8,31,39-41,50-55</sup>

**Recommendations**

Treatment of PCALCL should be tailored to the size and extent of tumors (Table 5). For solitary or grouped lesions, SE or RT is recommended as initial or first-line therapy. Both therapeutic approaches achieve a CR of at least 95%. Relapses after SE or RT occur in ~ 40% of patients and are equally frequent after both interventions. Relapses confined to the skin are not linked to worsened prognosis and do not require different treatment than initial tumors. Spontaneous regression of tumors has been observed in up to 44% of the PCALCL patients, most of them presenting with solitary or localized lesions, but also in patients with multifocal disease.<sup>4,6,8,23,25,56,57</sup> Onset of spontaneous tumor regression took place after a median period of 2 months (range, 1 week to 6 months). Patients should be informed that outcome after spontaneous regression of initial or recurrent tumors is excellent. It remains to be clarified whether patients with extensive limb disease should be treated in a different way than PCALCL at other localizations because recent studies reported worse prognosis for patients with extensive limb disease and PCALCL located on the leg.<sup>7,58</sup>

Multiagent chemotherapy has often been used as first-line therapy especially in multifocal PCALCL. CR rate to multiagent chemotherapy as initial therapy was 92% overall and 85% specifi-

cally for CHOP, which is the most common type of multiagent chemotherapy in malignant lymphomas. Relapses are very common and seen in 62% of all PCALCL patients treated with chemotherapy and in 71% of the patients initially treated with CHOP. No specific chemotherapeutic protocol has so far been shown to be superior. Thus multiagent chemotherapy and, in particular, CHOP can no longer be recommended as first-line therapy for multifocal or relapsing PCALCL limited to the skin.<sup>4,31</sup> As alternative therapy, low-dose MTX (5-25 mg/week), which is generally not myelosuppressive, has been proposed as first-line therapy for multifocal PCALCL.<sup>4,31</sup> Despite MTX having been proven to be effective in clearing LYP lesions, the reported experience in multifocal PCALCL is very limited and evidence is lacking for MTX in multifocal PCALCL despite a general expert consensus that its use is reasonable.<sup>4,38</sup> Systemic retinoids, including bexarotene, IFN- $\alpha$ , and thalidomide, have been described in anecdotal reports as effective treatment for multifocal PCALCL not responsive to other therapies. Maintenance therapy over months to years seems to be necessary with this immunomodulatory therapy.<sup>50,55</sup> Multiagent chemotherapy is only indicated for extracutaneous spread.

**Lymphomatoid papulosis therapy**

Topical steroids, photochemotherapy (psoralen-UVA light therapy [PUVA]), and low-dose MTX are the best documented and most common therapeutic approaches for LYP reported in the literature. The number of patients per therapeutic modality and the response rate to these therapies are given in Table 6. Anecdotal reports with only 1 or 2 patients and reports on other therapies, for which mostly < 10 patients were reported, are listed in Table 7.

**Phototherapy**

Even though phototherapy is one of the most common therapies in LYP, most reports do not provide details on the dosage or lack

**Table 6. LYP: therapies and results**

Therapy	References	No. of patients	CR, no. (%)	Relapse rate, no. (%)
PUVA	59,60,62-68,75	19	CR: 5/19 (26) PR: 13/19 (68) NR: 1/19 (5)	16/19 (84)
Systemic methotrexate	61,72-81	79	CR: 27/79 (34) PR: 52/79 (66) NR: 1/79 (0.1)	47/75 (63)
Topical steroids	63,84-90	25	CR: 3/25 (12) PR: 22/25 (88)	NA

NR indicates no response; and NA, not available.

**Table 7. LYP: other treatments**

Therapy	References
UVA, UVB	4,6,67,70,84,108-110
Topical tacrolimus	67
Isotretinoin (synonym: 13-cis-retinoic acid), alone or in combination with IFN- $\alpha$	76,92
Bexarotene, topical or systemic	66,95
Topical imiquimod 5%	80
IFN- $\alpha$ , IFN- $\gamma$	88,91,93,94
<b>Single-agent chemotherapy</b>	
Topical nitrogen mustard	6,82
Topical carmustine	13,8
Topical MTX	79
Topical cytotoxic alkyl phospholipid hexadecyl-phosphocholine	111
Multiagent chemotherapy	66,84
Anti-CD30-antibody (SGN30)	48
RT	10,12,15,77,84,85,98,99
Antibiotics (tetracyclines, penicillin, erythromycin)	84,86,89,98,108
Extracorporeal photopheresis	78,112
Photodynamic therapy	113
Acyclovir	114,115
Sulfones	84
Mistletoe	116

prolonged follow-up, making it difficult to draw conclusions on its effectiveness. Remarkably, there is no prospective study evaluating any form of phototherapy in LYP. Detailed data on response were available for 19 patients treated with PUVA or bath-PUVA. Thirteen of 19 patients (68%) experienced PR and 5 patients (26%) CR.<sup>59-68</sup> Relapses were observed in all patients shortly after cessation of treatment, except for 3 patients (16 of 19 patients; 84%). UVB light therapy was effective in 6 of 7 children.<sup>69</sup> UVA1 in a cumulative dose of 600-1800 J/cm<sup>2</sup> induced CR in 5 of 9 patients (56%) and PR with reduction of more than 50% of the lesions in the remaining 4 patients. Three of 7 patients, for whom follow-up was available, showed relapse after 1 to 20 months at follow-up.<sup>70</sup> Heliotherapy or exposure to sunlight was reported to be beneficial in 21 of 37 (57%) children.<sup>69,71,72</sup> In summary, most patients with LYP experience reduction in number of lesions and faster resolution after UV light exposure, but relapses are very common. Moreover, uncontrolled UV-light exposure will increase the risk for development of melanoma and nonmelanoma skin cancer.

### Chemotherapy

MTX is the most widely used single-agent chemotherapy to treat LYP patients with a total of 79 reported patients.<sup>61,72-81</sup> MTX was mostly used in a low-dose scheme (ie,  $\leq$  25 mg given at 1- to 4-week intervals).<sup>78</sup> In the largest retrospective study, including 40 patients with LYP, 44% of the patients did not develop new lesions and 42% of patients had only few new lesions during therapy with 15-25 mg MTX subcutaneous weekly.<sup>78</sup> After discontinuation of treatment, no relapse was observed in 10 of 40 patients (25%) during the follow-up period of 24 to 227 months. Side effects were reported in 77% of patients, including hepatic fibrosis in 5 of 10 patients treated with MTX for more than 3 years. In summary, MTX is effective in controlling the disease, but rapid relapse of lesions off drug in the majority of patients (47 of 75 patients; 63%) required maintenance therapy over several months or years.<sup>74,76-78</sup> Topical nitrogen mustard (aqueous solution or ointment-based vehicle), used frequently in MF, was reported to induce a sustained remission in only one of the 17 patients with

LYP (6%).<sup>72,78,82</sup> Topical BCNU (carmustine), a nitrosurea compound, was effective in suppressing disease activity in LYP with rapid reduction in the number, size, and life cycle time of lesions in 8 of 9 patients but without sustained remission.<sup>13,78</sup> A variety of multiagent chemotherapeutic regimens are able to induce regression of LYP lesions, but almost all patients had relapses shortly after withdrawal.<sup>4,8,10,11,15,66,83</sup>

### Corticosteroids

In daily practice, topical steroids are probably most often used for initial treatment. Treatment with topical steroids has been documented in detail in 25 patients with CR observed in only 3 of 25 patients (12%).<sup>63,72,84-90</sup> Topical steroids are often combined with other therapies, such as antibiotics or phototherapy.<sup>72</sup> In one study of children with LYP, with halobetasol or clobetasol propionate applied twice per day for 2 to 3 weeks followed by weekly pulsed application, complete resolution of all lesions occurred over 6 months, but 2 of the 3 children developed new lesions.<sup>87</sup> In summary, topical steroids alone or in combination with other therapies may hasten regression of lesions, but they do not prevent occurrence of new lesions. The reported data do not allow assessing effectiveness of topical steroids in LYP.<sup>72</sup> Oral corticosteroids were ineffective in all 5 patients reported in the literature.<sup>84</sup>

### Immunomodulatory therapy and retinoids

There are only very limited data on other therapies such as IFN- $\alpha$ , retinoids, bexarotene, and imiquimod in LYP.<sup>76,80,88,91-95</sup> CR was observed in 4 of 5 patients after 2-6 weeks of treatment with 3-15 MU IFN- $\alpha$  per week in an open trial.<sup>94</sup> Discontinuation resulted in relapses within 3-4 weeks and the necessity for maintenance therapy over 10-17 months.<sup>94</sup> Recent experimental data suggest that combined use of MTX and IFN- $\alpha$  could be useful in LYP.<sup>96</sup> Despite that expression of Toll-like receptors has been demonstrated in CD30<sup>+</sup> LPDs, the Toll-like receptor agonist imiquimod was reported only in 1 patient with CR, in whom all treated lesions resolved within 2 weeks.<sup>80,97</sup> CR was observed in one of 3 patients treated with oral bexarotene (150-650 mg, orally daily) in a prospective, uncontrolled, nonrandomized study.<sup>95</sup> Topical bexarotene resulted in CR in only one patient after 13 months and PR in 4 of 7 patients without data on follow-up.<sup>95</sup>

Radiotherapy has been used with various techniques and protocols.<sup>10,12,15,77,84,85,98,99</sup> Controversial results were seen with Grenz ray irradiation, which resulted in complete regression of treated lesions in 6 patients<sup>77</sup> but had no effect in another series of 3 patients.<sup>98</sup> Both Grenz ray treatment and orthovoltage therapy were followed by relapses.<sup>10,84,85,99</sup> One patient treated by electron beam irradiation experienced CR.<sup>12</sup>

### Other treatments

Table 7 lists other therapeutic approaches, for which only a very limited number of patients have been reported or detailed data on response, relapse, or outcome are lacking.

### Noninterventional strategy ("wait-and-see strategy")

Observation of natural disease course appears as a legitimate approach in LYP considering the excellent prognosis of LYP and the high recurrence rate after almost all therapies. Detailed data were reported for 5 adults and 11 children.<sup>6,8,10,60,67,71,72,86,98-100</sup> In 10 of 11 children, there was ongoing disease and CR was observed in only one child.<sup>71,99</sup> CR was reported in 5 adults, but no details on

**Table 8. Recommended definitions for future therapy studies in CD30+ LPDs**

Response	Definition
<b>I. Response in skin</b>	
A. LYP response in skin	
Complete response (CR)	100% clearance of skin lesions
Partial response (PR)	50%-99% clearance of skin disease from baseline without new larger and persistent nodule(s)† in those with papular disease only
Stable disease (SD)	< 50% increase to < 50% clearance in skin disease from baseline without new larger and persistent nodule(s) in those with papular disease only
Loss of response	Increase of skin score of greater than the sum of nadir plus 50% baseline score in patients with CR or PR
Increased disease activity (IDA)*	> 50% increase in skin disease from baseline without larger and persistent nodules†
Progressive disease (PD)	(1) Occurrence of larger and persistent nodule(s) (> 2 cm); and (2) extracutaneous spread
Relapse	Any disease recurrence in those with CR
B. PCALCL response in skin	
CR	100% clearance of skin lesions
PR	50%-99% clearance of skin disease from baseline without new tumors
SD	< 25% increase to < 50% clearance in skin disease from baseline
PD	(1) ≥ 25% increase in skin disease from baseline; or (2) loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score
Relapse	Any disease recurrence in those with CR
<b>II. Nodes: response in lymph nodes for LYP and PCALCL‡ (peripheral and central lymphnodes)</b>	
CR	All lymph nodes are now < 1.5 cm in greatest transverse (long axis) diameter by method used to assess lymph nodes at baseline or biopsy negative for lymphoma. In addition, lymph nodes that show lymphoma involvement by biopsy and < 1.5 cm in long axis diameter at baseline must now be ≤ 1 cm in diameter of the short axis or biopsy negative for lymphoma.
PR	Cumulative reduction ≥ 50% of the SPD [sum of the maximum linear dimension (major axis) × longest perpendicular dimension (minor axis)] of each abnormal lymph node at baseline and no new lymph node ≥ 1.5 cm or > 1.0 cm in the short axis if long axis is 1- to 1.5-cm diameter
SD	Fails to attain the criteria for CR, PR, and PD
PD§	(1) > 50% increase in SPD from baseline of lymph nodes; or (2) any new node ≥ 1.5 cm in greatest transverse diameter or > 1 cm in short axis diameter if 1- to 1.5-cm in long axis that is proven to be lymphoma histologically; or (3) loss of response: in those with PR or CR, > 50% increase from nadir in SPD of lymph nodes
Relapse	Any new lymph node ≥ 1.5 cm in long axis diameter in those with CR
<b>III. Visceral disease: response in viscera for LYP and PCALCL‡</b>	
CR	Liver or spleen or any organ considered involved at baseline should not be enlarged on physical examination and should be considered normal by imaging. No nodules should be present on imaging of liver or spleen. Any posttreatment mass must be determined by biopsy to be negative for lymphoma.
PR	≥ 50% regression in any splenic or liver nodules, or in measureable disease (SPD) in any organs abnormal at baseline. No increase in size of liver or spleen and no new sites of involvement.
SD	Fails to attain the criteria for CR, PR, or PD
PD§	(1) > 50% increase in size (SPD) of any organs involved at baseline; or (2) new organ involvement; or (3) loss of response: in those with PR or CR, > 50% increase from nadir in the size (SPD) of any previous organ involvement
Relapse	New organ involvement in those with CR

Skin tumor burden is assessed by counting the number of lesions before, during, and after therapeutic intervention regardless of morphology (macular, papular, or nodular; ulcerated or nonulcerated). Nodules or tumors > 2 cm should be captured separately. It may be particularly useful for the investigator to note the number of lesions in the body areas.<sup>20</sup> Total body photographs offer additional help in tracking lesions and making assessments.

\*The term increased disease activity (IDA) has been introduced for an increase of number of papulonodular lesions (< 2 cm), which does not imply impaired prognosis.

†Larger lesions are defined as > 2 cm in diameter. Persistent lesions are defined as lesions, which do not show spontaneous regression after 12 weeks.

‡It is still unsolved and a matter of debate whether involvement of lymph nodes and viscera in LYP exists at all or whether the occurrence of CD30+ lymphoma in lymph nodes and viscera represents ALCL, even if clonally related to LYP. Use of FDG-PET scan in this instance is compatible with other NHLs.

§Whichever criterion occurs first.

the length of disease course were available. None of the patients who were not treated developed second lymphoid neoplasms.

**Recommendations**

Because none of the therapies for LYP has been proven to alter the course of the disease and to prevent LYP-associated second lymphomas, abstinence from active therapeutic intervention is a legitimate first-line approach, especially in patients with a limited number of lesions (Table 5). For patients with numerous, disseminated, or stigmatizing lesions, phototherapy, in particular PUVA, and low-dose MTX are the best documented therapies for LYP. Various schemes for dosage (mostly low-dose, ie, 5-30 mg/week), application form (orally, subcutaneously, intramuscularly) and duration of treatment (weeks to years; with or without therapy-free intervals) are used to treat patients with LYP. Both, PUVA and MTX show high response rates with reduction and faster healing of lesions in the majority of patients, but sustained CR with regression of all

lesions is only rarely achieved. Relapse occurs rapidly within several weeks after dose reduction or withdrawal of treatment with recurrence rates of at least 40%. Similar results have been described for other therapeutic approaches evaluated on smaller series of patients, including interferons, retinoids, and antibiotics, but the evidence for those therapies is too low to recommend as first-line therapy. Because of the high proclivity of LYP to relapse, maintenance treatment may be required to control the disease but may be followed by long-term complications, such as the higher incidence of nonmelanoma skin cancer in patients treated with PUVA or development of hepatic fibrosis after long-term use of MTX, which requires monitoring of therapy.<sup>38</sup> For larger LYP lesions (arbitrarily defined as > 2 cm in diameter), which can persist for months, SE or RT is recommended as an alternative approach to a wait for spontaneous regression. In larger lesions or any lesion without spontaneous regression after months, however, progression to PCALCL should be considered.



**Table 9. Global Response Score for LYP and PCALCL**

Global Score*	Definition	Skin	Node	Viscera
<b>LYP</b>				
CR	Complete disappearance of all clinical evidence of disease	CR	CR or NI	NI
PR	Regression of measurable disease	CR	No CR but no PD	NI
SD	Failure to attain CR, PR, or PD representative of all disease	PR	No PD	NI
PD	Progressive disease	SD or IDA (Table 8, point I)	No PD	NI
Relapse	Recurrence disease in prior CR	PD in any category	PD in any category	PD in any category
		Relapse in any category	Relapse in any category	Relapse in any category
<b>PCALCL</b>				
CR	Complete disappearance of all clinical evidence of disease	CR	Both categories have CR or NI	Both categories have CR or NI
PR	Regression of measurable disease	CR	Both categories do not have a CR or NI but no PD	Both categories do not have a CR or NI but no PD
		PR	No category has a PD; and if either category is involved at baseline, at least one has a CR or PR	No category has a PD; and if either category is involved at baseline, at least one has a CR or PR
SD	Failure to attain CR, PR, or PD representative of all disease	PR	No category has a PD; and if either is involved at baseline, no CR or PR in either	No category has a PD; and if either is involved at baseline, no CR or PR in either
			CR/NI, PR, OR SD in any category and neither category has a PD	CR/NI, PR, OR SD in any category and neither category has a PD
PD	Progressive disease	PD in any category	PD in any category	PD in any category
Relapse	Recurrence disease in prior CR	Relapse in any category	Relapse in any category	Relapse in any category

NI indicates noninvolved.

Multiagent chemotherapy often leads to reduction or clearance of LYP lesions, but rapid recurrence of LYP shortly after or even during treatment is a consistent finding. Multiagent chemotherapy should therefore be avoided both because of its ineffectiveness and because of the side effects and long-term complications. LYP patients should be followed life-long because of the risk for second lymphoid neoplasms, which is reported to occur in 4%-25% of patients and may arise even decades after the manifestation of LYP and in the absence of LYP lesions. In this context, LYP is most commonly associated with MF.

## Conclusion

The presented recommendations for the management of CD30<sup>+</sup> LPDs are based on the data from small cohort series and case reports as well as the institutional experience of the members of the EORTC Cutaneous Lymphoma Task Force, ISCL, and USCLC. Despite more than 100 studies with therapeutic data on LYP and PCALCL that have been published, only a subset provides detailed information on the response to initial treatment, relapse rate, and outcome or long-term follow-up.

For PCALCL, SE and RT are recommended first-line therapies for solitary or grouped lesions. Multiagent chemotherapy is only indicated for extracutaneous tumor spread beyond locoregional lymph nodes. The best treatment for multifocal PCALCL has still to be determined because so far only anecdotal data for the previously reported therapeutic approaches have been reported. Prospective therapeutic studies are needed to clarify which therapy is most effective for multifocal and for relapsing PCALCL. Multiagent chemotherapy is only indicated for extracutaneous spread.

None of the available therapies for LYP appears unequivocally effective in preventing LYP-associated second lymphomas, although this point has not been systematically addressed in prospective studies. Therefore, abstention from active therapeutic intervention is a legitimate first-line approach in LYP. For patients requiring treatment, potential side effects, long-term complications, and costs of any therapeutic intervention have to be balanced against the favorable prognosis and outcome in most patients with CD30<sup>+</sup> LPD, respecting the concept of *primum nil nocere*.

One major limitation in assessing the effectiveness of therapeutic approaches in CD30<sup>+</sup> lymphomas relates to the proclivity of skin lesions in LYP and also in PCALCL for spontaneous regression. Therefore, the impact of any form of active treatment has always to be weighed against the possibility of spontaneous resolution. The regression of individual lesions in LYP cannot be assigned to a direct effect of treatment because spontaneous regression is the characteristic clinical feature and a diagnostic criterion for LYP. Relevant endpoints for therapeutic trials in LYP are CR defined as cessation of the disease (ie, absence of any new lesions). Therefore, we propose definitions for future studies in patients with CD30<sup>+</sup> LPDs to enable documentation of efficacy and better comparability of data (Tables 8 and 9). These definitions represent a modification of the recently reported clinical endpoints and response criteria in MF and Sézary syndrome.<sup>101</sup> They include counting the number of LYP lesions before, during, and after therapeutic intervention for an objective documentation of tumor burden and response to treatment. Increased disease activity has been introduced as a new term to describe an increase of papulonodular lesions of > 50% above baseline in patients with LYP during treatment. In contrast to progressive disease, defined as occurrence of large (> 2cm) and persistent nodules or extracutaneous spread

of disease, increased disease activity has no prognostic implication because the mere number of papulonodular skin lesions in LYP is not linked to prognosis but rather reflects extent and activity of disease.

Because of overlapping histologic and phenotypic features of CD30<sup>+</sup> LPDs, the final diagnosis has to be based on a synthesis of clinical, histologic, phenotypic, and molecular genetic findings. Because diagnostic workup requires a close collaboration between clinicians and dermatopathologists or pathologists, patients with CD30<sup>+</sup> LPDs should best be managed in centers specialized for cutaneous lymphomas. In regard to the lack of evidence for all reported therapies, prospective controlled and randomized trials are urgently needed to evaluate the effect of therapeutic interventions in CD30<sup>+</sup> LPDs.

## Authorship

Contribution: W.K., M.H.V., and R.W. conceived and designed the study, analyzed and interpreted the data, and supervised the study;

W.K., K.P., and A.C. acquired the data; W.K., M.H.V., and E.O. drafted the manuscript; W.K., K.P., S.O.-M. performed statistical analysis; and all authors critically revised the manuscript for important intellectual content.

Conflict-of-interest disclosure: M.B. and B.D. are members of the French scientific board of Cephalon. M.D. is a starting investigator initiated in trial of SGN35 with Seattle genetics. S.H. received research funds and has consulted for Seattle Genetics, Allos, Celgene, and Merck. Y.H.K. has consulted for Seattle Genetics, Allos, and Millennium. H.M.P. is on the advisory boards for Celgene and Merck. S.W. is on the advisory boards for Roche and Novartis. The remaining authors declare no competing financial interests.

Correspondence: Werner Kempf, Department of Dermatology, Cutaneous Lymphoma Study Group, University Hospital Zürich, Gloriestrasse 31, CH-8091 Zürich, Switzerland; e-mail werner.kempf@access.uzh.ch.

## References

- Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. *Blood*. 2005;105(10):3768-3785.
- Kempf W, Willemze R, Jaffe ES, Burg G, Kadin ME. CD30<sup>+</sup> T-cell lymphoproliferative disorders. In: LeBoit P, Burg G, Weedon D, Sarasin A, eds. *World Health Organization Classification of Tumours: Pathology and Genetics of Skin Tumours*. Lyon, France: IARC Press; 2006;179-181.
- Ralfkiaer E, Willemze R, Paulli M, Kadin ME. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., eds. *World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues* (4th ed). Lyon, France: IARC Press; 2008;300-301.
- Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. *Blood*. 2000;95(12):3653-3661.
- Kadin ME. Current management of primary cutaneous CD30<sup>+</sup> T-cell lymphoproliferative disorders. *Oncology (Williston Park)*. 2009;23(13):1158-1164.
- Vergier B, Beylot-Barry M, Pulford K, et al. Statistical evaluation of diagnostic and prognostic features of CD30<sup>+</sup> cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. *Am J Surg Pathol*. 1998;22(10):1192-1202.
- Benner MF, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. *Arch Dermatol*. 2009;145(12):1399-1404.
- Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30<sup>+</sup> cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. *J Am Acad Dermatol*. 2003;49(6):1049-1058.
- Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: a proposal for classification and guidelines for management and treatment. *J Am Acad Dermatol*. 1993;28(6):973-980.
- Cabanillas F, Armitage J, Pugh WC, Weisenburger D, Duvic M. Lymphomatoid papulosis: a T-cell dyscrasia with a propensity to transform into malignant lymphoma. *Ann Intern Med*. 1995;122(3):210-217.
- Laube S, Shah F, Marsden J. Consequences of misdiagnosis of lymphomatoid papulosis. *Eur J Cancer Care (Engl)*. 2006;15(2):194-198.
- Kaufmann T, Nisce LZ, Silver RT. Lymphomatoid papulosis: case report of a patient managed with radiation therapy and review of the literature. *Am J Clin Oncol*. 1992;15(5):412-416.
- Zackheim HS, Epstein EH Jr, Crain WR. Topical armustine therapy for lymphomatoid papulosis. *Arch Dermatol*. 1985;121(11):1410-1414.
- Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. *Oncology (Williston Park)*. 2010;24(7):574-587.
- Willemze R, Meyer CJ, Van Vloten WA, Scheffer E. The clinical and histological spectrum of lymphomatoid papulosis. *Br J Dermatol*. 1982;107(2):131-144.
- Saggini A, Gulia A, Argenyi Z, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8<sup>+</sup> cytotoxic T-cell lymphoma: description of 9 cases. *Am J Surg Pathol*. 2010;34(8):1168-1175.
- Kempf W. CD30<sup>+</sup> lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. *J Cutan Pathol*. 2006;33(suppl):158-170.
- Guitart J, Querfeld C. Cutaneous CD30 lymphoproliferative disorders and similar conditions: a clinical and pathologic prospective on a complex issue. *Semin Diagn Pathol*. 2009;26(3):131-140.
- Benner MF, Willemze R. Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin: retrospective analysis of 107 patients. *Br J Dermatol*. 2008;159(5):1148-1151.
- Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). *Blood*. 2007;110(2):479-484.
- Kaudewitz P, Stein H, Dallenbach F, et al. Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas: morphologic, immunohistologic, and clinical characteristics. *Am J Pathol*. 1989;135(2):359-367.
- Banerjee SS, Heald J, Harris M. Twelve cases of Ki-1 positive anaplastic large cell lymphoma of skin. *J Clin Pathol*. 1991;44(2):119-125.
- Beljaards RC, Kaudewitz P, Berti E, et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multi-center Study of 47 patients. *Cancer*. 1993;71(6):2097-2104.
- Krishnan J, Tomaszewski MM, Kao GF. Primary cutaneous CD30-positive anaplastic large cell lymphoma: report of 27 cases. *J Cutan Pathol*. 1993;20(3):193-202.
- de Bruin PC, Beljaards RC, van Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. *Histopathology*. 1993;23(2):127-135.
- Paulli M, Berti E, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin: clinicopathologic correlation and statistical analysis of 86 cases. A multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. *J Clin Oncol*. 1995;13(6):1343-1354.
- Trautmann C, Hahnemann HG, Hilbert ET, Detmar M, Gollnick H, Orfanos CE. [Large cell anaplastic Ki-1 positive lymphoma of the skin: 5 personal cases and review of the literature]. *Hautarzt*. 1995;46(1):28-34.
- Shah SA, Ormerod AD, Husain A, Kohle P, Culligan D. Primary cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma associated with renal cell carcinoma. *Br J Dermatol*. 1999;140(5):971-972.
- Berti E, Gianotti R, Alessi E. Primary anaplastic large cell lymphoma of the skin. *Dermatologica*. 1989;178(4):225-227.
- Yu JB, McNiff JM, Lund MW, Wilson LD. Treatment of primary cutaneous CD30<sup>+</sup> anaplastic large-cell lymphoma with radiation therapy. *Int J Radiat Oncol Biol Phys*. 2008;70(5):1542-1545.
- Chou WC, Su IJ, Tien HF, et al. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: special emphasis on the tumor response to 13-cis retinoic acid. *Cancer*. 1996;78(8):1805-1812.
- Kaufmann TP, Coleman M, Nisce LZ. Ki-1 skin lymphoproliferative disorders: management with radiation therapy. *Cancer Invest*. 1997;15(2):91-97.
- Chung HG, Chung YL, Kang JM, et al. CD30 (Ki-1)-positive large-cell cutaneous T-cell lymphoma with secondary xanthomatous changes after radiation therapy. *J Am Acad Dermatol*. 2003;48(2 suppl):S28-S30.
- Korean IV, Cho RI, Frueh BR, Elnor VM. Primary cutaneous anaplastic large cell lymphoma of the medial canthus and orbit. *Ophthalm Plast Reconstr Surg*. 2009;25(1):63-65.

35. Shimizu Y, Tanae K, Takahashi N, et al. Primary cutaneous anaplastic large-cell lymphoma presenting with hemophagocytic syndrome: a case report and review of the literature. *Leuk Res*. 2010;34(2):263-266.
36. Stenier C, Boulton A, Humblet Y, Ki-1 anaplastic primary cutaneous large-cell lymphoma. *Dermatology*. 1995;190(4):332-334.
37. Asha LK, Thomas D, Binitha MP, Nandakumar G. Primary cutaneous multifocal CD30+ anaplastic large cell lymphoma. *Indian J Dermatol Venereol Leprol*. 2006;72(5):376-378.
38. Fujita H, Nagatani T, Miyazawa M, et al. Primary cutaneous anaplastic large cell lymphoma successfully treated with low-dose oral methotrexate. *Eur J Dermatol*. 2008;18(3):360-361.
39. Sheehy O, Catherwood M, Pettengell R, Morris TC. Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis. *Leuk Lymphoma*. 2009;50(8):1389-1391.
40. Shehan JM, Kalaaji AN, Markovic SN, Ahmed I. Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma. *J Am Acad Dermatol*. 2004;51(1):103-110.
41. Boudova L, Kazakov DV, Jindra P, et al. Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman. *J Cutan Pathol*. 2006;33(8):584-589.
42. Isogai R, Fukao M, Kawada A. Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in an elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VN-COP-B) therapy. *J Dermatol*. 2007;34(8):556-560.
43. Diamantidis MD, Papadopoulos A, Kaiafa G, et al. Differential diagnosis and treatment of primary, cutaneous, anaplastic large cell lymphoma: not always an easy task. *Int J Hematol*. 2009;90(2):226-229.
44. Rijlaarsdam JJ, Huijgens PC, Beljaards RC, Bakels V, Willemze R. Oral etoposide in the treatment of cutaneous large-cell lymphomas: a preliminary report of four cases. *Br J Dermatol*. 1992;127(5):524-528.
45. Brice P, Cazals D, Mounier N, et al. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. *Leukemia*. 1998;12(2):213-219.
46. Yamane N, Kato N, Nishimura M, Ito M, Yanagi T, Osawa R. Primary cutaneous CD30+ anaplastic large-cell lymphoma with generalized skin involvement and involvement of one peripheral lymph node, successfully treated with low-dose oral etoposide. *Clin Exp Dermatol*. 2009;34(5):e56-e59.
47. Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. *Blood*. 2008;111(4):1848-1854.
48. Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. *Clin Cancer Res*. 2009;15(19):6217-6224.
49. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. *N Engl J Med*. 2010;363(19):1812-1821.
50. French LE, Shapiro M, Junkins-Hopkins JM, Vittorio CC, Rook AH. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. *J Am Acad Dermatol*. 2001;45(6):914-918.
51. Hazneci E, Aydin NE, Dogan G, Turhan IO. Primary cutaneous anaplastic large cell lymphoma in a young girl. *J Eur Acad Dermatol Venereol*. 2001;15(4):366-367.
52. Keun YK, Woodruff R, Sangueta O. Response of CD30+ large cell lymphoma of skin to bexarotene. *Leuk Lymphoma*. 2002;43(5):1153-1154.
53. Didona B, Benucci R, Amerio P, Canzona F, Rienzo O, Cavalieri R. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). *Br J Dermatol*. 2004;150(6):1198-1201.
54. Ehst BD, Dreno B, Vonderheid EC. Primary cutaneous CD30+ anaplastic large cell lymphoma responds to imiquimod cream. *Eur J Dermatol*. 2008;18(4):467-468.
55. Lee JH, Cheng AL, Lin CW, Kuo SH. Multifocal primary cutaneous CD30+ anaplastic large cell lymphoma responsive to thalidomide: the molecular mechanism and the clinical application. *Br J Dermatol*. 2009;160(4):887-889.
56. Bernier M, Bagot M, Broyer M, Farcet JP, Gaulard P, Wechsler J. Distinctive clinicopathologic features associated with regressive primary CD30 positive cutaneous lymphomas: analysis of 6 cases. *J Cutan Pathol*. 1997;24(3):157-163.
57. Kumar S, Pittaluga S, Raffeld M, Guerrero M, Seibel NL, Jaffe ES. Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. *Pediatr Dev Pathol*. 2005;8(1):52-60.
58. Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. *Arch Dermatol*. 2009;145(6):667-674.
59. Wantzin GL, Thomsen K. PUVA-treatment in lymphomatoid papulosis. *Br J Dermatol*. 1982;107(6):687-690.
60. Lange-Wantzin G, Thomsen K, Hou-Jensen K. Lymphomatoid papulosis: a follow-up study. *Acta Derm Venereol*. 1984;64(1):46-51.
61. Lange Wantzin G, Thomsen K. Methotrexate in lymphomatoid papulosis. *Br J Dermatol*. 1984;111(1):93-95.
62. Barnadas MA, Lopez D, Pujol RM, Garcia-Patos V, Currell R, de Moragas JM. Pustular lymphomatoid papulosis in childhood. *J Am Acad Dermatol*. 1992;27(4):627-628.
63. Wolf P, Cohen PR, Duvic M. Ambivalent response of lymphomatoid papulosis treated with 8-methoxypsoralen and UVA. *J Am Acad Dermatol*. 1994;30(6):1018-1020.
64. Volkenandt M, Kerscher M, Sander C, Meurer M, Rocken M. PUVA-bath photochemotherapy resulting in rapid clearance of lymphomatoid papulosis in a child. *Arch Dermatol*. 1995;131(9):1094.
65. Gambichler T, Maushagen E, Menzel S. Foil bath PUVA in lymphomatoid papulosis. *J Eur Acad Dermatol Venereol*. 1999;13(1):63-65.
66. Perna AG, Jones DM, Duvic M. Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. *Clin Lymphoma*. 2004;5(3):190-193.
67. Korpusik D, Ruzicka T. [Clinical course and therapy of lymphomatoid papulosis: experience with 17 cases and literature review]. *Hautarzt*. 2007;58(10):870-881.
68. Hoetzenecker W, Guenova E, Hoetzenecker K, Yazdi A, Rocken M, Berneburg M. Successful treatment of recalcitrant lymphomatoid papulosis in a child with PUVA-bath photochemotherapy. *Eur J Dermatol*. 2009;19(6):646-647.
69. de Souza A, Camilleri MJ, Wada DA, Appert DL, Gibson LE, el-Azhary RA. Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. *J Am Acad Dermatol*. 2009;61(6):993-1000.
70. Calzavara-Pinton P, Venturini M, Sala R. Medium-dose UVA1 therapy of lymphomatoid papulosis. *J Am Acad Dermatol*. 2005;52(3):530-532.
71. Van Neer FJ, Toonstra J, Van Voorst Vader PC, Willemze R, Van Vloten WA. Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch Cutaneous Lymphoma Working Group. *Br J Dermatol*. 2001;144(2):351-354.
72. Nijsten T, Curjel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. *Arch Dermatol*. 2004;140(3):306-312.
73. Lynch PJ, Saied NK. Methotrexate treatment of pityriasis lichenoides and lymphomatoid papulosis. *Cutis*. 1979;23(5):634-636.
74. Everett MA. Treatment of lymphomatoid papulosis with methotrexate. *Br J Dermatol*. 1984;111(5):631.
75. Wantzin GL, Thomsen K, Brandrup F, Larsen JK. Lymphomatoid papulosis: development into cutaneous T-cell lymphoma. *Arch Dermatol*. 1985;121(6):792-794.
76. Thomsen K, Wantzin GL. Lymphomatoid papulosis: a follow-up study of 30 patients. *J Am Acad Dermatol*. 1987;17(4):632-636.
77. Christensen HK, Thomsen K, Vejlsgaard GL. Lymphomatoid papulosis: a follow-up study of 41 patients. *Semin Dermatol*. 1994;13(3):197-201.
78. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. *J Am Acad Dermatol*. 1996;34(3):470-481.
79. Bergstrom JS, Jaworsky C. Topical methotrexate for lymphomatoid papulosis. *J Am Acad Dermatol*. 2003;49(5):937-939.
80. Hughes PS. Treatment of lymphomatoid papulosis with imiquimod 5% cream. *J Am Acad Dermatol*. 2006;54(3):546-547.
81. Romero-Mate A, Martin-Fragueiro L, Minano-Medrano R, Martinez-Moran C, Arias-Palomo D, Borbujo J. Persistent agmination of lymphomatoid papulosis evolving to classical lesions of lymphomatoid papulosis. *J Am Acad Dermatol*. 2009;61(6):1087-1088.
82. Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. *J Am Acad Dermatol*. 1989;20(3):416-428.
83. Scheen SR 3rd, Doyle JA, Winkelmann RK. Lymphoma-associated papulosis: lymphomatoid papulosis associated with lymphoma. *J Am Acad Dermatol*. 1981;4(4):451-457.
84. Sanchez NP, Pittelkow MR, Muller SA, Banks PM, Winkelmann RK. The clinicopathologic spectrum of lymphomatoid papulosis: study of 31 cases. *J Am Acad Dermatol*. 1983;8(1):81-94.
85. Sina B, Burnett JW. Lymphomatoid papulosis: case reports and literature review. *Arch Dermatol*. 1983;119(3):189-197.
86. Zirbel GM, Gellis SE, Kadin ME, Esterly NB. Lymphomatoid papulosis in children. *J Am Acad Dermatol*. 1995;33(5):741-748.
87. Paul MA, Krowchuk DP, Hitchcock MG, Jorizzo JL. Lymphomatoid papulosis: successful weekly pulse superpotent topical corticosteroid therapy in three pediatric patients. *Pediatr Dermatol*. 1996;13(6):501-506.
88. Kagaya M, Kondo S, Kamada A, Yamada Y, Matsusaka H, Jimbow K. Localized lymphomatoid papulosis. *Dermatology*. 2002;204(1):72-74.
89. Dalle S, Balme B, Thomas L. Lymphomatoid papulosis localized to the face. *Dermatol Online J*. 2006;12(3):9.
90. Bories N, Thomas L, Phan A, et al. [Lymphomatoid papulosis in childhood: six case reports and a literature review]. *Ann Dermatol Venereol*. 2008;135(10):657-662.

91. Proctor SJ, Jackson GH, Lennard AL, Marks J. Lymphomatoid papulosis: response to treatment with recombinant interferon alfa-2b. *J Clin Oncol*. 1992;10(1):170.
92. Wyss M, Dummer R, Dommann SN, et al. Lymphomatoid papulosis: treatment with recombinant interferon alfa-2a and etretinate. *Dermatology*. 1995;190(4):288-291.
93. Yagi H, Tokura Y, Furukawa F, Takigawa M. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma. *J Invest Dermatol*. 1996;107(6):827-832.
94. Schmuth M, Topar G, Illersperger B, Kowald E, Fritsch PO, Sepp NT. Therapeutic use of interferon-alpha for lymphomatoid papulosis. *Cancer*. 2000;89(7):1603-1610.
95. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. *Dermatology*. 2003;206(2):142-147.
96. Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. *Arch Dermatol*. 2011;147(4):443-449.
97. Knol AC, Ehst BD, Domp Martin A, et al. Toll-like receptor 2, 4, 7 and 9 expression in primary cutaneous CD30+ T-cell lymphoma. *Br J Dermatol*. 2009;161(6):1414-1416.
98. Thomsen K, Hjort G, Svendsen D. Lymphomatoid papulosis. *Dermatologica*. 1972;144(2):65-74.
99. Scarisbrick JJ, Evans AV, Woolford AJ, Black MM, Russell-Jones R. Regional lymphomatoid papulosis: a report of four cases. *Br J Dermatol*. 1999;141(6):1125-1128.
100. Deroo-Berger MC, Skowron F, Ronger S, et al. Lymphomatoid papulosis: a localized form with acral pustular involvement. *Dermatology*. 2002;205(1):60-62.
101. Olsen EA, Whittaker S, Kim YH, et al. Clinical endpoints and response criteria in mycosis fungoides and Sézary syndrome: a Consensus Statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC) and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer (EORTC). *J Clin Oncol*. 2011;29(18):2598-2607.
102. Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. *Cancer*. 1999;86(7):1368-1376.
103. Tomaszewski MM, Moad JC, Lupton GP. Primary cutaneous Ki-1 (CD30) positive anaplastic large cell lymphoma in childhood. *J Am Acad Dermatol*. 1999;40(5):857-861.
104. Blume JE, Stoll HL, Cheney RT. Treatment of primary cutaneous CD30+ anaplastic large cell lymphoma with intralesional methotrexate. *J Am Acad Dermatol*. 2006;54(5 suppl):S229-S230.
105. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. *Clin Lymphoma Myeloma*. 2006;7(1):51-58.
106. Meisenheimer JL. Novel use of 308-nm excimer laser to treat a primary cutaneous CD30+ lymphoproliferative nodule. *J Drugs Dermatol*. 2007;6(4):440-442.
107. Honma M, Hashimoto M, Iwasaki T, et al. Primary cutaneous anaplastic large cell lymphoma successfully treated with local thermotherapy using pocket hand warmers. *J Dermatol*. 2008;35(11):748-750.
108. el-Azhary RA, Gibson LE, Kurtin PJ, Pittelkow MR, Muller SA. Lymphomatoid papulosis: a clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor gene rearrangement studies. *J Am Acad Dermatol*. 1994;30(2):210-218.
109. Assaf C, Hirsch B, Wagner F, et al. Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations. *J Invest Dermatol*. 2007;127(8):1898-1904.
110. Coelho JD, Afonso A, Feio AB. Regional lymphomatoid papulosis in a child: treatment with a UVB phototherapy handpiece. *J Cosmet Laser Ther*. 2010;12(3):155-156.
111. Dummer R, Krasovec M, Roger J, Sindermann H, Burg G. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. *J Am Acad Dermatol*. 1993;29(6):963-970.
112. Wollina U. Lymphomatoid papulosis treated with extracorporeal photochemotherapy. *Oncol Rep*. 1998;5(1):57-59.
113. Rodrigues M, McCormack C, Yap LM, et al. Successful treatment of lymphomatoid papulosis with photodynamic therapy. *Australas J Dermatol*. 2009;50(2):129-132.
114. Baumgartner G, Duschet P, Schwarz T, Patsch H, Gschnait F, Stacher A. Lymphomatoid papulosis: remission following intravenously administered acyclovir. *Dermatologica*. 1986;172(6):305-309.
115. Burg G, Klepzig K, Kaudewitz P, Wolff H, Braun-Falco O. [Acyclovir in mycosis fungoides and lymphomatoid papulosis]. *Hautarzt*. 1986;37(10):533-536.
116. Seifert G, Tautz C, Seeger K, Henze G, Laengler A. Therapeutic use of mistletoe for CD30+ cutaneous lymphoproliferative disorder/lymphomatoid papulosis. *J Eur Acad Dermatol Venereol*. 2007;21(4):558-560.